TITLE

ODAC rejects dutasteride, dutasteride for prostate cancer prevention

PUB. DATE
December 2010
SOURCE
Hem/Onc Today;12/25/2010, Vol. 11 Issue 24, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on the rejection of an application to approve GlaxoSmithKline's dutasteride and Merck's finasteride for prostate cancer chemoprevention.
ACCESSION #
56533928

 

Related Articles

  • Finasteride does not reduce PSA's role in prostate cancer detection. Bankhead, Charles // Urology Times;Oct98, Vol. 26 Issue 10, p1 

    Deals with the findings of the Proscar Long-Term Efficacy and Safety Study that treatment of BPH with finasteride does not reduce the effectiveness of PSA testing for prostate cancer. Details on the study; PSA levels reduced by finasterides; Comments on the findings of the study.

  • Dutasteride reduces prostate cancer risk. Kuritzky, Louis // Internal Medicine Alert;5/17/2010, p71 

    The article focuses on the study which examines the efficacy of dutasteride and finasteride drugs to treat patients with prostate cancer.

  • Finasteride Prevents Low-Grade Prostate Cancers, but Does Not Reduce Mortality. EBELL, MARK H.; HUGHES, LAUREN S. // American Family Physician;12/1/2013, Vol. 88 Issue 11, p744 

    The article provides an answer to a question of whether the use of finasteride affect overall mortality or grade-specific survival rates following a diagnosis of prostate cancer.

  • Finasteride may inhibit PCa progression, invasion. Wirschubsky, Zvi // Urology Times;Jun99, Vol. 27 Issue 6, p14 

    Focuses on the results of research on the effectiveness of finasteride in the prevention of prostate cancer progression and invasion. Cell proliferation and protease production inhibited by finasteride; Inhibition observed in all primary prostate cancer cultures tested.

  • Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143. Homma, Yukio; Kaneko, Masashi // JNCI: Journal of the National Cancer Institute;06/04/97, Vol. 89 Issue 11, p803 

    Studies the inhibition of rat prostate carcinogenesis by finasteride, a 5alpha-reductase inhibitor. Incidence of prostate carcinoma in rats fed with finasteride-containing diets; Analysis of intrapostatic dihydrotestosterone content; Dose dependence for the chemopreventive activity of finasteride.

  • Experts show wide range of opinion on PCa prevention trial.  // Urology Times;Aug2003, Vol. 31 Issue 8, p1 

    Reports on the percentage reduction of prostate cancer incidence in men treated with finasteride in the U.S. Details on the era in prostate cancer prevention; Application of findings by urologists to clinical practice; Development of prostate cancer. INSET: Oral chemotherapy promising for PCa.

  • QOL stable during prophylactic finasteride.  // PharmacoEconomics & Outcomes News;9/29/2012, Issue 663, p9 

    The article discusses an analysis of the Prostate Cancer Prevention Trial (PCPT) which found that prostate cancer prophylaxis with finasteride has no impact on quality of life (QOL).

  • From the literature: Treatment for male pattern baldness delays prostate cancer.  // Formulary;Sep2003, Vol. 38 Issue 9, p527 

    Reports that reductase inhibitor finasteride, a drug for treatment of baldness can prevent or delay the appearance of prostate cancer according to researchers from the University of Texas Health Science Center in San Antonio, Texas. Risk of adverse effects on sexual function; Inhibition of the...

  • Trial Watch.  // Nature Reviews Cancer;Aug2003, Vol. 3 Issue 8, p553 

    Cites a study by I.M. Thomas and colleagues published in the 17 July 2003 issue of the journal 'New England Journal of Medicine,' on influence of finasteride on development of prostate cancer. Reduction of androgenic stimulation by finasteride; Inhibition of conversion of testosterone to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics